文献速递心境障碍

利用脑磁共振成像预测重性抑郁障碍的治疗结局:一项Meta分析

Predicting treatment outcomes in major depressive disorder using brain magnetic resonance imaging: a meta-analysis.
PubMed 文献 · Mol Psychiatry · 2024-08-26

该Meta分析检索建库至2023年7月22日的文献,分别汇总13项临床特征研究与44项脑MRI特征研究以预测重性抑郁障碍治疗结局。临床研究合并AUC为0.73,MRI研究为0.89;MRI研究敏感度高于临床研究(0.78 vs 0.62)。静息态功能MRI特异度高于任务态功能MRI(0.79 vs 0.69),结构MRI与功能MRI之间及不同干预之间预测性能无显著差异。

要点

  • MRI预测MDD治疗结局的合并AUC为0.89,临床特征研究为0.73。
  • MRI研究敏感度0.78高于临床研究的0.62(Z=3.42,P=0.001)。
  • 静息态功能MRI特异度0.79高于任务态功能MRI的0.69(Z=-2.86,P=0.004)。

核心结论

  • 作者认为治疗前脑MRI特征有望预测重性抑郁障碍的治疗结局,表现优于临床特征。
  • 任务态功能MRI研究总体预测效用低于静息态功能MRI数据。
  • 抗抑郁药与电休克治疗结局由重叠但不同的网络层面指标预测。
  • 未来研究需用多种MRI特征预测结局,并明确影像特征预测结局是普遍性的还是随治疗而异。

研究设计与样本

  • 文献检索自数据库建库至2023年7月22日,纳入使用治疗前临床特征或脑MRI特征预测重性抑郁障碍治疗结局的研究。
  • 分别对临床研究(13项)与MRI研究(44项)进行两项Meta分析。
  • 采用Meta回归探索协变量效应,并比较临床与MRI组、不同MRI模态及干预亚组间的预测性能。

主要发现

  • 13项临床研究Meta分析的曲线下面积(AUC)为0.73,44项MRI研究的AUC为0.89。
  • MRI研究敏感度高于临床研究(0.78 vs 0.62,Z=3.42,P=0.001)。
  • MRI研究中静息态功能MRI特异度高于任务态功能MRI(0.79 vs 0.69,Z=-2.86,P=0.004)。
  • 结构MRI与功能MRI之间、不同干预之间未发现预测性能的显著差异。
  • 抗抑郁药研究中预测治疗结局的MRI特征主要位于边缘系统与默认网络,电休克治疗研究主要限于边缘系统网络。

关键数值与推荐

  • 临床研究(13项)预测治疗结局的合并AUC为0.73。
  • MRI研究(44项)预测治疗结局的合并AUC为0.89。
  • MRI研究敏感度0.78 vs 临床研究0.62(Z=3.42,P=0.001)。
  • 静息态功能MRI特异度0.79 vs 任务态功能MRI 0.69(Z=-2.86,P=0.004)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出多数纳入研究样本量小,因此有必要开展Meta分析以识别最稳健的发现与影像模态。
  • 作者提出未来研究需用多种MRI特征预测结局,并明确影像特征预测结局是普遍性的还是随治疗而异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Recent studies have provided promising evidence that neuroimaging data can predict treatment outcomes for patients with major depressive disorder (MDD). As most of these studies had small sample sizes, a meta-analysis is warranted to identify the most robust findings and imaging modalities, and to compare predictive outcomes obtained in magnetic resonance imaging (MRI) and studies using clinical and demographic features. We conducted a literature search from database inception to July 22, 2023, to identify studies using pretreatment clinical or brain MRI features to predict treatment outcomes in patients with MDD. Two meta-analyses were conducted on clinical and MRI studies, respectively. The meta-regression was employed to explore the effects of covariates and compare the predictive performance between clinical and MRI groups, as well as across MRI modalities and intervention subgroups. Meta-analysis of 13 clinical studies yielded an area under the curve (AUC) of 0.73, while in 44 MRI studies, the AUC was 0.89. MRI studies showed a higher sensitivity than clinical studies (0.78 vs. 0.62, Z = 3.42, P = 0.001). In MRI studies, resting-state functional MRI (rsfMRI) exhibited a higher specificity than task-based fMRI (tbfMRI) (0.79 vs. 0.69, Z = -2.86, P = 0.004). No significant differences in predictive performance were found between structural and functional MRI, nor between different interventions. Of note, predictive MRI features for treatment outcomes in studies using antidepressants were predominantly located in the limbic and default mode networks, while studies of electroconvulsive therapy (ECT) were restricted mainly to the limbic network. Our findings suggest a promise for pretreatment brain MRI features to predict MDD treatment outcomes, outperforming clinical features. While tasks in tbfMRI studies differed, those studies overall had less predictive utility than rsfMRI data. Overlapping but distinct network-level measures predicted antidepressants and ECT outcomes. Future studies are needed to predict outcomes using multiple MRI features, and to clarify whether imaging features predict outcomes generally or differ depending on treatments.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Long F, Chen Y, Zhang Q, et al. Predicting treatment outcomes in major depressive disorder using brain magnetic resonance imaging: a meta-analysis. Mol Psychiatry. 2024. PMID: 39187625. doi:10.1038/s41380-024-02710-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。